Почетна › Множен миелом › Илиноис
Клинички испитувања за Множен миелом во Илиноис
31 студии за Множен миелом бараат учесници на локации во Илиноис.
Градови во Илиноис
- Chicago22 студии
- Cicero6 студии
- Evanston4 студии
- Waukegan4 студии
- Springfield4 студии
- Decatur3 студии
- Bloomington3 студии
- Aurora3 студии
- Galesburg3 студии
- Peoria3 студии
- North Peoria3 студии
Официјален текст на студијата (англиски)
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- и уште 13
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT06948084A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Chicago
- Research Site, Park Ridge
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07391657A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- University of Chicago Medical Center /ID# 278863, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07409246A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Chicago Medical Center, Chicago
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT04973605A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Northwestern University, Chicago
- University of Chicago, Chicago
Се регрутираФаза 4
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT05201781A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- City of Hope Chicago, Zion
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07258511A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Rush University System for Health, Chicago
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07518186A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University Of Illinois Medical Center, Chicago
- Loyola University Medical Center, Maywood
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT05552222Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT05789303TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America-Chicago, Chicago
Се регрутираФаза 2
Возраст 12 и постари · Сите полови · Ажурирано 22.9.2026 · NCT02693535Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT06297226Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
- University of Illinois at Chicago, Chicago
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 28.8.2026 · NCT05344833MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Endeavor Health - Swedish Hospital, Chicago
- Endeavor Health - Evanston Hospital, Evanston
- Endeavor Health - Glenbrook Hospital Ambulatory Care Center, Glenview
- и уште 6
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 24.8.2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- и уште 40
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT04566328AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Chicago
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Chicago
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 14.8.2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Loyola University Medical Center, Maywood
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 12.8.2026 · NCT07280013Mosaic Trial for Stem Cell Transplant Recipients
- Northwestern University Feinberg School of Medicine, Chicago
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 3.8.2026 · NCT06960993Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
- Loyola University Chicago, Maywood
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 22.7.2026 · NCT07236502A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Hope And Healing Cancer Services /ID# 268536, Hinsdale
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 13.7.2026 · NCT05650632Integrated Cancer Repository for Cancer Research
- Rush-Copley Cancer Care Center, Aurora
- Rush-Copley Healthcare Center, Yorkville
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 19 до 110 · Сите полови · Ажурирано 29.6.2026 · NCT02012699Personalized Autologous Transplant for Multiple Myeloma
- University Illinois Chicago, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 15.6.2026 · NCT04483206Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Anthony's Health, Alton
- Rush - Copley Medical Center, Aurora
- Saint Joseph Medical Center, Bloomington
- и уште 41
Се регрутираФаза 3
Сите возрасти · Сите полови · Ажурирано 10.6.2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- University of Chicago, Chicago
- University of Illinois Medical Center at Chicago, Chicago
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 4.6.2026 · NCT05243797Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
Се регрутираФаза 1
Возраст 13 и постари · Сите полови · Ажурирано 5.5.2026 · NCT04771572Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
- University of Chicago Medical Center, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 1.4.2026 · NCT05862012Hypofractionation (Radiation) Trial for Multiple Myeloma
- The University of Chicago Comprehensive Cancer Center, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 30.3.2026 · NCT06270888A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 24.3.2026 · NCT04988555Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Northshore University Health System, Evanston
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 23.2.2026 · NCT05974150A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
- City of Hope at Chicago, Zion
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст 18 и постари · Сите полови · Ажурирано 20.2.2026 · NCT07225738Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
- University of Illinois Cancer Center, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 18.12.2025 · NCT05192122Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.